ArticleScientific reports2026
A novel Umezawaea tangerina endophyte reveals anti-colorectal cancer activity and a rich biosynthetic landscape.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Colorectal cancer is the second leading cause of cancer-related mortality worldwide, highlighting the need for novel anticancer agents with fewer side effects. Endophytic actinobacteria (EA) are recognized as prolific producers of bioactive natural products. This study evaluated the anticancer potential of fractionated extracts from a novel endophytic actinobacterial strain, IKBG05 (genus Umezawaea), isolated from Cerasus microcarpa. Ethyl acetate extracts of submerged cultures were fractionated, and their cytotoxic effects were assessed against SW480 and HCT116 colorectal cancer cell lines. Among six fractions, F2 and F3' showed moderate cytotoxic effects consistent with early-stage screening of semi-purified fractions, with IC₅₀ values ranging from 188 to 416 µg/mL. At the tested concentration, fraction F2 produced 2.48- and 2.67-fold higher growth inhibition in SW480 and HCT116 cells, respectively, compared with normal fibroblasts. F2 treatment was also associated with increased intracellular ROS levels and induction of apoptosis, particularly in HCT116 cells, comparable to the reference drug 5-fluorouracil.In parallel, genome mining of three available Umezawaea genomes identified 85 putative biosynthetic gene clusters (BGCs), suggesting considerable biosynthetic potential. This study provides the first genome-wide prediction of BGCs across currently available Umezawaea genomes and reports preliminary evidence of anticancer activity in extracts from strain IKBG05. These findings support further purification and characterization of the bioactive constituents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.